Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      +30 YEARS' GLOBAL EXPERIENCE
      ACROSS MULTIPLE INDICATIONS1-4

       

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      UK-BCM-240113. DOP: January 2025.

      Understanding and addressing unmet need in chronic migraine

      • It is estimated that 190,000 migraine attacks are experienced every day in the UK6
      • Migraine affects approximately 23.3% of adults in the UK, with a higher prevalence in females than in males7,8
      • As many as 86 million workdays could be lost annually in the UK due to migraine-related absenteeism and presenteeism7
      • Chronic migraine is a debilitating disease, affecting 1.4-2.2% of adults worldwide9

      CHRONIC MIGRAINE IS A COMPLEX NEUROLOGICAL DISEASE REQUIRING APPROPRIATE EFFECTIVE MANAGEMENT – INCLUDING TREATMENT OR REFERRALS TO IMPROVE PATIENT OUTCOMES2,10,11

      Chronic migraine is defined by the International Headache Society (IHS) as:10

      Chronic migraine is a complex and fluctuating disease that debilitates patients when it is not treated effectively12,13

      Patients with chronic migraine exhibit large variations in the frequency of their migraines13

      cm-aw2

      Adapted from Serrano D et al, 201713

      Over 70% of patients experience variation in the frequency of their headaches13

      Associated with many comorbidities, including anxiety, depression and sleep disorders.12, 14

      Common comorbidities

      The leading cause of disability among neurological disorders in people aged 15-49 years15

      It can be challenging to correctly diagnose patients.16 Learn about differential diagnosis

      Common symptoms of migraine

      Migraine is a complex condition with a wide variety of symptoms.10 It can be classified as migraine without aura, characterised by headache with specific symptoms and features, or migraine with aura, characterised by transient focal neurological symptoms that typically precede and/or accompany the headache.10 Some patients also experience a prodromal and a postdromal phase.10

      table one understanding 2

      A small proportion (<10%) of women with migraine have attacks, typically without aura, associated with their menstrual cycle.10 Attacks occurring during menstruation are usually longer and accompanied by more severe nausea than those occurring at other times of the menstrual cycle.10

      table understanding cm 2

      Chronic migraine is a complex neurological disease requiring appropriate effective management - including treatment or referrals to improve patient outcomes2,10,11

      CM: chronic migraine.

      THREE STEPS TO MAKING A CHRONIC MIGRAINE DIAGNOSIS

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed March 2024
      6. Steiner T J, Scher A I et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519-527
      7. The Work Foundation. Society's headache: the socioeconomic impact of migraine. Available at: theworkfoundation.com. Accessed March 2024
      8. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976
      9. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      10. International Headache Society (IHS). International classification of headache disorders (3rd edition) guidelines. Available at: ihs-headache.org. Accessed March 2024
      11. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123
      12. Adams A M, Serrano D et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563-578
      13. Serrano D, Lipton R B et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101
      14. 1Buse D C, Rains J C et al. Sleep disorders among people with migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(1):32-45
      15. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      16. Dodick D W, Loder E W et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2016;56(5):821-834

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed March 2024
      6. Steiner T J, Scher A I et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519-527
      7. The Work Foundation. Society's headache: the socioeconomic impact of migraine. Available at: theworkfoundation.com. Accessed March 2024
      8. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976
      9. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      10. International Headache Society (IHS). International classification of headache disorders (3rd edition) guidelines. Available at: ihs-headache.org. Accessed March 2024
      11. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123
      12. Adams A M, Serrano D et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563-578
      13. Serrano D, Lipton R B et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101
      14. 1Buse D C, Rains J C et al. Sleep disorders among people with migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(1):32-45
      15. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      16. Dodick D W, Loder E W et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2016;56(5):821-834

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: March 2024. UK-BCM-240036

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.